Acquisition

June 22, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Intimation of Acquisition of 10,00,000 equity shares of M/s Curexis Ventures Private Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue. Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject; we, Zota Health Care Limited (the “Company”), would like to inform you that the Company has acquired 10,00,000 equity shares of M/s Curexis Ventures Private Limited (“Curexis”), Wholly Owned Subsidiary of the Company, by way of subscription to the right issue. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 are annexed herewith as Annexure-I. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl: a/a Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Annexure-I Particulars Details Name of the target entity, details in brief such as size, i. Name of the Target Entity: Curexis Ventures turnover etc. Private Limited (‘Curexis’) ii. Business of the Target Entity: established as a drug manufacturing, development, and marketing company. CUREXIS is engaged in the business of running retail pharmacy stores under the brand name of “SKIA” offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products. iii. Financial details: as per the audited financial statements for the Financial Year 2025-26, the turnover of Curexis was Rs. 1.18 Lakhs and the total paid up share capital was Rs. 1 Lakh. Whether the acquisition would fall within related party No, the acquisition does not fall within the ambit of transaction(s) and whether the promoter/ promoter related party transactions. The promoter/ promoter group/ group companies have any interest in the entity group/ group companies do not have any interest in being acquired? If yes, nature of interest and details Curexis and the said transaction is done at arm’s thereof and whether the same is done at “arm’s length” length basis. Industry to which the entity being acquired belongs Pharmaceutical Objects and effects of acquisition (including but not The Company has made investment in Curexis as a limited to, disclosure of reasons for acquisition of target part of strategic investment, expansion of SKIA stores entity, if its business is outside the main line of business and to mitigate the working capital requirements of of the listed entity); Curexis. Post to this acquisition, Curexis continues to remain as the Wholly Owned Subsidiary of the Company. Brief details of any governmental or regulatory N.A. approvals required for the acquisition Indicative time period for completion of the acquisition On June 22, 2026, the Company has acquired the said 10,00,000 equity shares of Curexis by subscription to the right issue. Nature of consideration - whether cash consideration Cash consideration by way of acquisition of Equity or share swap and details of the same; Shares. Cost of acquisition or the price at which the shares are Cost of acquisition for subscription of 10,00,000 acquired Equity Shares offered on right basis is Rs. 20.00/- per equity share (including premium of Rs. 10.00/- per equity share) aggregating to Rs. 2,00,00,000.00/-. Percentage of shareholding / control acquired and / or The Company has acquired 10,00,000 equity shares number of shares acquired of Curexis. Post to this acquisition, Curexis continues to remain as the Wholly-owned Subsidiary of the Company. Brief background about the entity acquired in terms of Curexis was incorporated on February 25, 2025, products/line of business acquired, date of domiciled in India; engaged in drug manufacturing, incorporation, history of last 3 years turnover, country development, and marketing company. CUREXIS is in which the acquired entity has presence and any other engaged in the business of running retail pharmacy significant information (in brief) stores under the brand name of “SKIA” offering wide range of Pharmaceutical, Nutraceutical, Cosmetic, Ayurvedic and OTC products. During last three financial years, the details of turnover of Curexis were as follows: FY 2025-26 Rs. 1.18 Lakhs FY 2024-25 Rs. NIL FY 2023-24: N.A.